

2023 PBM Legislation

	House			Senate		
	<i>Energy & Commerce</i>	<i>Education & Workforce</i>	<i>Ways & Means</i>	<i>Commerce</i>	<i>Health, Education, Labor and Pensions</i>	<i>Finance</i>
Delinking					(Not in text but considering for commercial)	(Part D)
Transparency in Coverage Rule	(Commercial)	(Commercial)	(Commercial)			
Enhanced ERISA Compensation Reporting for PBMs/TPAs		(Commercial)				
Spread Pricing Ban	(Medicaid)			(All Markets)	(Commercial)	(Medicaid)
Rebate Pass-Through	(Medicaid ⁱ)			(All Markets)	(Commercial)	(Medicaid ⁱ /Part D)
Pharmacy DIR Limitations				(All Markets)		(Part D)
PBM Pricing and Fee Transparency to Plans/Sponsors	(Commercial)	(Commercial)	(Commercial)	(All Markets)	(Commercial)	(Part D)
Cost-sharing Limits	(Commercial)		(Part D)			(Part D)
Limits on Step Therapy					(Commercial)	

ⁱ Both House Energy & Commerce and Senate Finance Committee include Medicaid spread pricing proposals – the effect of these policies is to require pass-through pricing to plan sponsor. As a result, we have noted as such in this document.